OncoMatch/Clinical Trials/NCT07398937
Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC
Is NCT07398937 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Serplulimab + chemotherapy and Nivolumab + chemotherapy for resectable stage ii-iiia squamous nsclc.
Treatment: Serplulimab + chemotherapy · Nivolumab + chemotherapy — This trial is a randomized, controlled, multicenter, open-label study, planning to enroll 116 subjects with resectable stage II-IIIa squamous NSCLC confirmed by histopathology or cytology, aiming to evaluate the efficacy and safety of serplulimab compared to nivolumab combined with chemotherapy in neoadjuvant therapy. This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1036.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitizing mutation
EGFR sensitivity mutation
Required: ALK rearrangement
ALK gene rearrangement
Required: ROS1 rearrangement
ROS1 gene rearrangement
Disease stage
Required: Stage II, IIIA
Performance status
WHO/ECOG 0–1
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify